STOCK TITAN
  1. Home
  2. Sec-filings
  3. KYMR
  4. [Form 4] Kymera Therapeutics, Inc. Insider Trading Activity

Kymera (KYMR) CEO sells 50K shares after exercising options under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. Chief Executive Officer Nello Mainolfi reported an option exercise and related stock sale. He exercised stock options to acquire 50,000 shares of Common Stock at an exercise price of $2.08 per share, then sold 50,000 Common shares at an average price of $119.00 per share.

Following these transactions, he directly owned 666,568 Common shares. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated March 24, 2026, and the options involved were fully vested and exercisable.

Positive

  • None.

Negative

  • None.
Insider Mainolfi Nello
Role Chief Executive Officer
Sold 50,000 shs ($5.95M)
Approx. gross sale proceeds $5.95M
Approx. exercise cost $104K
Approx. pre-tax spread $5.85M
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 45,559 $0.00 $0.00
Exercise Stock Option (Right to Buy) 4,441 $0.00 $0.00
Exercise Common Stock 50,000 $2.08 $104K
Sale Common Stock 50,000 $119.00 $5.95M
Holdings After Transaction: Stock Option (Right to Buy) — 104,284 shares (Direct); Common Stock — 666,568 shares (Direct)
Footnotes (2)
  1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person.
  2. F2. The shares underlying this stock option are fully vested and exercisable.
Shares sold 50,000 shares Common Stock open-market sale on 2026-07-07 at $119.00
Sale price $119.00 per share Price for 50,000 Common shares sold on 2026-07-07
Options exercised 50,000 shares Shares acquired via option exercise on 2026-07-07
Option exercise price $2.08 per share Conversion or exercise price for stock options exercised
Post-transaction holdings 666,568 shares Common Stock directly owned after transactions
Rule 10b5-1 plan date March 24, 2026 Trading plan governing these transactions
Option expiration date November 13, 2029 Expiration for stock options at $2.08 exercise price
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with underlying security title Common Stock."
open-market sale financial
"transaction_action: "open-market sale" for 50,000 shares of Common Stock at $119.0000 per share."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security" for the option transactions."
fully vested and exercisable financial
"The shares underlying this stock option are fully vested and exercisable."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Kymera (KYMR) CEO Nello Mainolfi do in this Form 4 filing?
Nello Mainolfi exercised stock options for 50,000 Kymera shares at $2.08 per share and sold 50,000 Common shares at $119.00 per share. These transactions are reported as part of his direct ownership in the company.

How many Kymera (KYMR) shares does the CEO hold after these transactions?
After the reported transactions, CEO Nello Mainolfi directly holds 666,568 shares of Kymera Common Stock. This figure comes from the Form 4 and reflects his direct ownership position following the option exercise and subsequent share sale.

At what prices did the Kymera (KYMR) CEO exercise and sell shares?
Nello Mainolfi exercised stock options at an exercise price of $2.08 per Kymera share and sold 50,000 Common shares at an average price of $119.00 per share. These prices are explicitly disclosed in the Form 4 filing.

Were the Kymera (KYMR) CEO’s trades made under a Rule 10b5-1 plan?
Yes. The Form 4 states the transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026. Such plans are pre-arranged trading programs that schedule transactions in advance under predetermined conditions.

What type of securities were involved in the Kymera (KYMR) CEO’s Form 4?
The filing covers Kymera Common Stock and related stock options described as “Stock Option (Right to Buy).” The options were fully vested and exercisable, and their exercise led to the acquisition of 50,000 Common shares reported in the non-derivative transactions table.

What do the stock options in the Kymera (KYMR) Form 4 represent?
The stock options, labeled “Stock Option (Right to Buy),” give the CEO the right to purchase Kymera Common Stock at a conversion price of $2.08 per share until their stated expiration date. The filing notes the underlying option shares are fully vested and exercisable.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mainolfi Nello
(Last)(First)(Middle)
C/O KYMERA THERAPEUTICS, INC.
500 NORTH BEACON STREET, 4TH FLOOR
(Street)
WATERTOWN MASSACHUSETTS 02472
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/07/2026M(1)50,000A$2.08716,568D
Common Stock07/07/2026S(1)50,000D$119666,568D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$2.0807/07/2026M(1)45,559 (2)11/13/2029Common Stock45,559$090,000D
Stock Option (Right to Buy)$2.0807/07/2026M(1)4,441 (2)11/13/2029Common Stock4,441$014,284D
Explanation of Responses:
1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person.
2. The shares underlying this stock option are fully vested and exercisable.
/s/ Bruce Jacobs, as Attorney-in-Fact07/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR